title: Rationale and clinical use of multitargeting anticancer agents.
abstract: Human solid tumors contain genetically distinct subpopulations of tumor cells that can be enriched under selective pressure of specific treatments. This heterogeneous nature reflects the dynamism of drug response and it represents a fundamental driver of resistance. Moreover, the complexity of cancer disease is increased by the activity of cross-talking, redundant signaling pathways, escape pathways and compensatory events, which triggers activation of secondary growth and survival. Broad multi-targeted approaches are requested to overcome a complex, heterogeneous, and dynamic disease such as cancer.
authors.affiliation: Digestive Molecular Clinical Oncology Research Unit, Medical Oncology, Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Melisi
authors.forename: Geny
authors.initials: G
authors.lastname: Piro
authors.forename: Anna
authors.initials: A
authors.lastname: Tamburrino
authors.forename: Carmine
authors.initials: C
authors.lastname: Carbone
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Tortora
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors